Sai Parenterals Limited (SAIPARENT) Q2 FY27 Financial Results: PAT ₹8 & Revenue ₹182 Cr

Investor Takeaways

• Revenue reached ₹182 crores in Q1 FY27, up from ₹56 crores standalone, driven by recent acquisitions.
• EBITDA was ₹27 crores with gross margin at 41.8%, reflecting improved operational efficiency.
• Net debt reduced to ₹310 crores as of June 2027, though additional leverage is anticipated for acquisitions.
• FY27 revenue target of [amount context mismatch] crores reaffirmed with ~17% EBITDA margin guidance; full capacity benefits expected in FY28.

Overall Tone: Neutral

Key Financial Highlights

What Changed

Sai Parenterals reported consolidated revenue of ₹182 crores for Q1 FY27, a significant increase from ₹56 crores in the standalone entity, primarily due to strategic acquisitions. The company acquired 60% stakes in Saicriti Pharma and Prathyak Laboratories for ₹83 crores and ₹15 crores respectively, aiming to expand critical care injectables capacity and accelerate R&D. Gross margin improved to 41.8%, and EBITDA stood at ₹27 crores. Net profit was ₹8 crores, with EPS at [amount not verified]The company reaffirmed its FY27 revenue target of ₹750 crores and ~17% EBITDA margin, noting that full capacity benefits will materialize in FY28. Debt was reduced to ₹310 crores as of June 2027, though additional leverage is expected for future acquisitions. Quarterly performance showed sequential revenue decline from ₹197.93 crores in Q4FY26, but profitability improved compared to the loss of [amount context mismatch] crores in Q3FY26.

Peer Comparison

Sai Parenterals trades at a premium valuation compared to peers, with a higher P/E ratio, but maintains competitive ROE and ROCE.

Risks & Concerns

• No specific risks identified in this filing.

Quarterly Trend